Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2359 • 2014 ACR/ARHP Annual Meeting
CGEN-15001, a Novel Immunomodulatory Fusion Protein of the B7 Family Induces Immune Tolerance and Shows Efficacy in Mouse Models of Rheumatoid Arthritis and Psoriasis
Iris Hecht¹, Kay McNamee², Aviad Keren³, Joseph R. Podojil⁴, Ilan Vaknin¹, Anat Oren¹, Galit Rotman¹, Eyal Neria¹, Stephen D. Miller⁴, Amos Gilhar³ and Richard O. Williams², ¹Compugen Ltd., Tel Aviv, Israel, ²Kennedy Institute of Rheumatology, Oxford University, Oxford, United Kingdom, ³Technion Institute of Technology, Haifa, Israel, ⁴Microbiology-Immunology, Northwestern University, Chicago, IL
Background/Purpose CGEN-15001 is an Fc-fusion protein consisting of the extracellular domain of a novel B7-like protein, discovered based on shared family characteristics. CGEN-15001 inhibits T…
Abstract Number: 886 • 2014 ACR/ARHP Annual Meeting
Measuring Rheumatoid Arthritis Remission: Which Index of Disease Activity Best Predicts Work Status?
Nancy A. Baker¹, Heather Eng², Juan (June) Feng², Jason Lyons², Yong Gil Hwang³, Kimberly P. Liang⁴ and Larry W. Moreland⁵, ¹Department of Occupational Therapy, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Disease remission is the goal of treat-to-target initiatives in rheumatoid arthritis (RA). There are multiple indices to measure disease activity and remission status including…
Abstract Number: 324 • 2014 ACR/ARHP Annual Meeting
Regulation of TNF-α-Mediated Activation of Rheumatoid Synovial Fibroblasts By Transcription Factor Snail
Chrong-Reen Wang^1,2, Shih-Yao Chen³, Ai-Li Shiau⁴, I-Ming Jou^5,6, Ming-Fei Liu^1,2 and Chao-Liang Wu³, ¹Internal Medicine, National Cheng Kung University Medical College, Tainan, Taiwan, ²Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, ³Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan, ⁴Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan, ⁵Orthopedics, National Cheng Kung University Medical College, Tainan, Taiwan, ⁶Orthopedics, National Cheng Kung University Hospital, Tainan, Taiwan
Background/Purpose: Transcription factor Snail plays active roles in various biological functions and is involved in many disease states. We hypothesized that this molecule regulates TNF-α-mediated…
Abstract Number: 2340 • 2014 ACR/ARHP Annual Meeting
Human Osteoclasts Are Mobilized in Erosive Arthritis of Epstein-Barr Virus-Infected Humanized NOD/Shi-Scid/IL-2Rγ^null Mice
Yosuke Nagasawa¹, Natsumi Ikumi², Takamasa Nozaki¹, Hirotake Inomata¹, Kenichi Imadome³, Noboru Kitamura¹, Mitsuhiro Iwata¹, Shigeyoshi Fujiwara⁴ and Masami Takei¹, ¹Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ³Department of Infectious Diseases, National Research Institute for Child Health and Development, Tokyo, Japan, ⁴Department of Iinfectious Diseases, National Research Institute for Child Health and Development, Tokyo, Japan
Background/Purpose Various studies of the relationship between Epstein-Barr virus (EBV) and rheumatoid arthritis (RA) have not produced convincing evidence. Many human viruses do not infect…
Abstract Number: 849 • 2014 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years
J. Wollenhaupt¹, J. Silverfield², E.B. Lee³, S.P. Wood⁴, K. Terry⁴, H. Nakamura⁵, K. Kwok⁶, A. Anisfeld⁶, C. Nduaka⁴, R. Riese⁴ and L. Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Tokyo, Japan, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
Abstract Number: 338 • 2014 ACR/ARHP Annual Meeting
Bombina Variegate peptide8/Prokineticin 2: A Novel Arthritis-Inducible Chemokine
Haruyasu Ito, Ken Yoshida, Kentaro Noda and Daitaro Kurosaka, Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by the joint destruction. Chemokines play important roles as monocyte and neutrophil recruiters in RA.…
Abstract Number: 2165 • 2014 ACR/ARHP Annual Meeting
Myeloid-Derived Suppressor Cells in Rheumatoid Arthritis: Friend or Foe?
Fanlei Hu¹, Chunqing Guo², Xiang-Yang Wang² and Zhanguo Li¹, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of Human and Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, VA
Background/Purpose Although myeloid-derived suppressor cells (MDSCs) have been linked to T-cell tolerance, their role in rheumatoid arthritis (RA) remains exclusive. Here, we investigated the potential…
Abstract Number: 519 • 2014 ACR/ARHP Annual Meeting
Patterns of Tocilizumab Use and Safety in Patients with Rheumatoid Arthritis: Interim Results from a Multinational Observational Study
Boulos Haraoui¹, Gustavo Casado², Elke Theander³, Laszlo Czirják⁴, Andrew Taylor⁵, Peter Button⁶, Lykke Hinsch Gylvin⁷ and Roberto Caporali⁸, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Hospital Militar Central, Buenos Aires, Argentina, ³Skane University Hospital Malmö, Lund University, Malmö, Sweden, ⁴University of Pécs, Pécs, Hungary, ⁵Royal Perth Hospital, Perth, Australia, ⁶Roche Products Pty Limited, Dee Why, Australia, ⁷F. Hoffmann-La Roche, Basel, Switzerland, ⁸Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
Background/Purpose: Tocilizumab (TCZ) is indicated for the treatment of patients with RA who have had inadequate responses to DMARDs either as monotherapy (Mono) or in…
Abstract Number: 135 • 2014 ACR/ARHP Annual Meeting
Comparison of the Ultrasonography Images and Synovial Pathology of the Joints in Patients with Rheumatoid Arthritis Treated with Biological Agents
Asami Abe¹, Hajime Ishikawa¹ and Akira Murasawa², ¹Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²Niigata Rheumatic Center, Shibata, Japan
Background/Purpose: An early diagnosis and tight disease control have increased in importance in the era of biological therapy for rheumatoid arthritis (RA). Ultrasonography (US) of…
Abstract Number: 2879 • 2014 ACR/ARHP Annual Meeting
Epigallocatechin-3-Gallate (EGCG) Suppresses IL-1β-Induced IL-6 and IL-8 Synthesis By Selectively Inhibiting TAK1 Activation in Human Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh¹, Sharayah Riegsecker², Sadiq Umar¹ and Salahuddin Ahmed¹, ¹Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, ²Department of Pharmacology, University of Toledo, Toledo, OH
Background/Purpose: In rheumatoid arthritis (RA), the role of interleukin-1β (IL-1β) signaling proteins (IRAK-1/TAK-1/TRAF-6) proximal to IL-1 receptor in mediating proinflammatory response is not completely understood.…
Abstract Number: 1972 • 2014 ACR/ARHP Annual Meeting
Analysis of Anakinra in Primary Human Cell Systems Reveals an in Vitro Signature for Skin-Related Side Effects
Ellen L. Berg, Alison O'Mahony and Mark A Polokoff, BioSeek, South San Francisco, CA
Background/Purpose The therapeutic options for treatment of rheumatic diseases have grown and now include a variety of inflammatory pathway inhibitors, with diverse mechanisms, but having…
Abstract Number: 517 • 2014 ACR/ARHP Annual Meeting
Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients in Canada: Interim Results
Boulos Haraoui¹, Shahin Jamal², Vandana Ahluwalia³, Tarang Manchanda⁴ and Majed Khraishi⁵, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Department of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³William Osler Health Center, Brampton, ON, Canada, ⁴Hoffmann-La Roche Canada, Mississauga, ON, Canada, ⁵Nexus Clinical Research, St John's, NF, Canada
Background/Purpose Tocilizumab (TCZ) has been approved for the treatment of adults with rheumatoid arthritis (RA) either as monotherapy or as combination with disease-modifying antirheumatic drugs…
Abstract Number: 123 • 2014 ACR/ARHP Annual Meeting
Combination with Joint Power Doppler Signals with Anti-Citrullinated Peptide Antibody Predicts Joint Destruction in Rheumatoid Arthritis
Yohei Kirino¹, Maasa Hama¹, Kaoru Minegishi-Takase¹, Yosuke Kunishita¹, Daiga Kishimoto¹, Ryusuke Yoshimi¹, Yukiko Asami¹, Atsushi Ihata², Shigeru Ohno³, Atsuhisa Ueda¹, Mitsuhiro Takeno⁴ and Ishigatsubo Yoshiaki¹, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ³Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ⁴Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
Background/Purpose , Categorizing RA patients who require intensive treatments is highly warranted to optimize the therapy and to avoid overtreatments. We here evaluated the use…
Abstract Number: 2817 • 2014 ACR/ARHP Annual Meeting
Histone Deacetylase One Contributes to the Auto-Aggressive Phenotype of Rheumatoid Arthritis
Sarah Hawtree¹, Munitta Muthana¹, J. Mark Wilkinson², Anthony G. Wilson¹ and Mohammed Akil³, ¹Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ²Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, United Kingdom, ³Rheumatology Department, Sheffield South Yorkshire, United Kingdom
Background/Purpose Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease that affects synovial joints. A key characteristic of RA is hyperplasia of fibroblast-like synoviocytes (FLS)…
Abstract Number: 1845 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-Naive Patients with Early Rheumatoid Arthritis: 2-Year Clinical and Radiographic Results from a Randomized, Placebo-Controlled Trial
Gerd Burmester¹, William Rigby², Ronald F. van Vollenhoven³, Jonathan Kay⁴, Andrea Rubbert-Roth⁵, Ricardo Blanco⁶, Ariella Kelman⁷, Sophie Dimonaco⁸ and Nina Mitchell⁸, ¹Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Karolinska Institute, Stockholm, Sweden, ⁴UMass Memorial Medical Center, Worcester, MA, ⁵University of Cologne, Cologne, Germany, ⁶Hospital Marques de Valdecilla, Santander, Spain, ⁷Genentech, South San Francisco, CA, ⁸Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Treatment with tocilizumab (TCZ) in combination with MTX or as monotherapy (Mono) in MTX-naive patients (pts) with early RA resulted in improved signs and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].